Companies/AU/AAI

ALCOA CORPORATION

Last · ASXA$56.79-2.51 (-4.23%)live · yahoo · 3h ago
Vol 314.4K ≈ 17.86M
Market capA$15.0B263.9M sh
P/E · TTM8.0fwd 5.0 · eps 7.10
Beta1.74vs S&P 500
Div yield0.67%annual · TTM
52w range
A$54.14A$117.87
Volume314.4Ksession

Issuer

Legal nameALCOA CORPORATION
HQAustralia (AU)
ListingAU AAI
ISINUS0138721065 +1
SectorMaterials
IndustryMetals & Mining
SIC3334
CurrencyUSD
Entity registrylei:549300T12EZ1F6PWWU29
CIK0001675149
LinkedIn
Employees14,900
AddressAlcoa Corp. 201 Isabella Street 15212-5858, Pittsburgh +412 315 2900
Headline financial metrics
Revenue$13.6B
Operating income$1.2B
Net income$1.3B
Free cash flow$352.0M
Operating margin8.9%
Net margin9.4%
Return on equity17.3%
PeriodTTM 2026-06-30
Loading chart…

OpenFilings analyst

Our analyst

Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.

Improving fundamentals are offset by modest underlying growth and material execution, leverage and pricing risks.

Latest call · Q2 2026

Hold: Teva is executing a credible recovery, but the 2024 outlook implies only 2%-6% revenue growth excluding the $500 million Sanofi upfront payment, while adjusted EBITDA is guided to $4.5-$5.0 billion and adjusted EPS to $2.20-$2.50. AUSTEDO, UZEDY and AJOVY provide genuine growth, but North American generics are only expected to stabilize amid ongoing price erosion, launch competition and declining Truxima revenue; leverage remains elevated at 3.45x net debt/EBITDA.

Themes
  • Pivot To Growth
  • Austedo
  • Uzedy
  • Ajovy
  • North America Generics
  • Biosimilars
+2

Near term

AUSTEDO 2024 revenue guidance is $1.5 billion, following 27% growth to $1.2 billion in 2023; direct-to-consumer promotion and titration-pack improvements could support prescription growth.

UZEDY has 2024 revenue guidance of $80 million, with early uptake coming substantially from oral risperidone patients and additional switching within long-acting risperidone.

AJOVY has 2024 revenue guidance of $500 million after 16% growth in 2023.

Biosimilar Humira launch timing depends on FDA clearance of Alvotech's Iceland facility; management said there will be no Sanofi milestone payment in 2024.

Q4 2023 GAAP results benefited materially from the $500 million Sanofi upfront payment, making reported growth and margin comparisons less representative.

2024 revenue and earnings are expected to progress gradually, with the second half slightly higher than the first half.

Longer term

Management targets AUSTEDO revenue of $2.5 billion by 2027 and expects five biosimilar launches over the next four years, including Stelara targeted for February 2025.

Teva plans 13 complex-generic launches in 2024-2025, but management explicitly acknowledged that several launches will face competition and are primarily intended to offset annual U.S. price erosion.

The 2027 framework calls for a 30% operating margin, mid-single-digit revenue growth and 2.0x net debt/adjusted EBITDA; achieving this depends on operating leverage after current investment in sales, marketing and R&D.

Olanzapine LAI is fully enrolled with 675 patients and 2,030 injections completed without a PDSS signal to date; Phase 3 results are expected in the second half of 2024 and could materially affect the pipeline thesis.

Debt reduction is progressing, with net debt down to $16.6 billion from $18.4 billion at year-end 2022, but approximately $3.4 billion matures around October 2026 and refinancing costs could remain high.

The planned TAPI divestiture should sharpen strategic focus, but management characterized its margin impact as broadly neutral rather than an immediate earnings catalyst.

Red flags

Management declined to characterize North American generics as definitively growing, saying the outcome could be flat or growth depending on future price erosion and the number of competitors entering launches.

The 2024 revenue midpoint of $16.0 billion is only 4.3% above 2023 revenue excluding the Sanofi upfront payment, while operating expenses remain elevated at 27%-27.5% of revenue as Teva invests for future growth.

The Humira opportunity remains contingent on FDA approval of Alvotech's facility and uncertain PBM access; management acknowledged multiple variables around approval, launch timing and penetration.

A Q&A discussion disclosed errors in a contingent consideration liability and related expenses. Management said they were not material and did not affect non-GAAP results or cash flow, but a remediation plan for internal controls is still in progress.

North American generics remain exposed to structurally challenging pricing, and declining Truxima revenue adds pressure before the new complex-generic portfolio scales.

The call provided limited quantitative detail on Korlym's launch, the economics of the TAPI divestiture or the revenue contribution expected from individual biosimilars.

Forward outlook

revenue

15.7–16.3 $billion

FY 2024

official guidance

revenue growth

2–6 pct

FY 2024

official guidance

gross margin

53–54 pct

FY 2024

official guidance

ebitda

4.5–5 $billion

FY 2024

official guidance

adjusted eps

2.2–2.5 $per share

FY 2024

official guidance

revenue

1.5 $billion

FY 2024

official guidance

revenue

0.08 $billion

FY 2024

official guidance

revenue

0.5 $billion

FY 2024

official guidance

revenue

2.5 $billion

FY 2027

management target

operating margin

30 pct

FY 2027

management target

Recommendation history

OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.

From latest 10-K · 2024-02-21

  • Net Margin Sharply Negative
  • Cash Runway Medium

Red flags

  • Net Margin Sharply Negative — Net margin -6.2%
  • Cash Runway Medium — Cash runway ~2.1 years

Upcoming earnings

1 event
10:00 PM UTC+2
Period
Sep 2026
Est. EPS
$1.50
Est. revenue
3.8B

Earnings transcripts

12 of 193 recent

Press & signals

3 of 5 recent
  • Satelight

    China and the new era of critical minerals diplomacy

  • Satelight

    Alcoa Corporation Announces Closing of Debt Offering to Finance

  • Satelight

    Alcoa Corporation Announces Pricing of Debt Offering to Finance

The rest of this company's wire — with summaries and source links — is part of Pro.

See plans

Documents

FormReporting forFiledFlags
—2026-12-31≈0
—2026-12-31≈0
2026-09-152026-09-170